Australian TGA

This is a discussion paper. It does not reflect the views of the Committee. It should not be cited.

99.               The Australian Department of Health, Disability and Ageing Therapeutic Goods Administration (TGA) have also been aware of an increasing number of cases in scientific literature, by consumers who had taken products containing G. gummi-gutta or HCA. One of the five cases which reported liver transplantation was an Australian case. In response, the TGA completed an investigation into the risk of liver injury for the ingredient G. gummi-gutta (G. cambogia) and its naturally occurring component HCA. They concluded that “available evidence shows that there may be a rare risk of liver injury from taking Garcinia gummi-gutta (Garcinia cambogia).” (TGA, 2024a).

100.               The TGA states that they will continue to monitor the issue and considering further regulatory action following a consultation on proposed requirements for a label warning. The consultation has ended, and final changes commenced 1^st of March 2025, and a 12-month transition period was given to ensure product compliance. These changes are: 1) replacing “rare” with “very rare”; 2) provisions relating to liver-related warnings, and 3) references to the plant part for G. gummi-gutta will be changed from “rind of the fruit” to “fruit peel” to align with the plant parts in the TGA Code Tables (TGA, 2024b).